Tag: Eisai

Eisai and BMS Enter Into Strategic Collaboration for MORAb-202 Antibody Drug Conjugate

Bristol Myers Squibb will pay $650 million U.S. dollars to Eisai including $200 million U.S. dollars as payment toward Eisai research and development expenses.